The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells

British Journal of Cancer

Volumn 110, Issue 5, 2014, Pages 1278-1287

  Henderson, D J P ^a   Byrne, A ^a   Dulla, K ^b   Jenster, G ^c   Hoffmann, R ^b   Baillie, G S ^a   Houslay, M D ^d  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b PHILIPS RESEARCH LABORATORIES   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

CAMP; Cyclic adenosine mono phosphate; PDE4D; PDE4D7; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; CYCLIC AMP PHOSPHODIESTERASE; CYCLIC AMP PHOSPHODIESTERASE 4D7; MESSENGER RNA; UNCLASSIFIED DRUG; SMALL INTERFERING RNA;

ARTICLE; CANCER GROWTH; CELL MEMBRANE; CELL PROLIFERATION; DOWN REGULATION; ENZYME ACTIVITY; GENE STRUCTURE; IMMUNOFLUORESCENCE TEST; IMPEDANCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; PROSTATE CANCER CELL LINE; SEQUENCE ALIGNMENT;

3',5'-CYCLIC-AMP PHOSPHODIESTERASES; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MEMBRANE; CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; DOWN-REGULATION; HUMANS; ISOENZYMES; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 84895826827     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.22     Document Type: Article

References (50)

1. Amorino GP, Parsons SJ (2004) Neuroendocrine cells in prostate cancer. Crit Rev Eukaryot Gene Expr 14(4): 287-300. (Pubitemid 40221058)
2. Bolger G, Erdogan S, Jones R, Loughney K, Scotland G, Hoffmann R, Wilkinson I, Farrell C, Houslay M (1997) Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene. Biochem J 328(2): 539-548. (Pubitemid 27515598)
3. Cho-Chung YS, Nesterova MV (2005) Tumor reversion: protein kinase a isozyme switching. Ann N Y Acad Sci 1058(1): 76-86.
4. Conti M, Beavo J (2007) Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 76: 481-511.
5. Desiniotis A, Schäfer G, Klocker H, Eder IE (2010) Enhanced antiproliferative and proapoptotic effects on prostate cancer cells by simultaneously inhibiting androgen receptor and cAMP-dependent protein kinase A. Int J Cancer 126(3): 775-789.
6. Feldman BJ, Feldman D (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1(1): 34-45. (Pubitemid 33741879)
7. Flacke J-P, Flacke H, Appukuttan A, Palisaar R-J, Noldus J, Robinson BD, Reusch HP, Zippin JH, Ladilov Y (2013) Type 10 soluble adenylyl cyclase is overexpressed in prostate carcinoma and controls proliferation of prostate cancer cells. J Biol Chem 288(5): 3126-3135.
8. Foley R, Marignol L, Keane JP, Lynch TH, Hollywood D (2011) Androgen hypersensitivity in prostate cancer: Molecular perspectives on androgen deprivation therapy strategies. Prostate 71(5): 550-557.
9. Francis SH, Blount MA, Corbin JD (2011) Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiol Rev 91(2): 651-690.
10. Gretarsdottir S, Thorleifsson G, Reynisdottir S, Manolescu A, Jonsdottir S, Jonsdottir T, Gudmundsdottir T, Bjarnadottir S, Einarsson O, Gudjonsdottir H, Hawkins M, Gudmundsson G, Gudmundsdottir H, Andrason H, Gudmundsdottir A, Sigurdardottir M, Chou T, Nahmias J, Goss S, Sveinbjornsdottir S, Valdimarsson E, Jakobsson F, Agnarsson U, Gudnason V, Thorgeirsson G, Fingerle J, Gurney M, Gudbjartsson D, Frigge M, Kong A, Stefansson K, Gulcher J (2003) The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. Nat Genet 37(5): 131-138. (Pubitemid 37187631)
11. Grignon DJ, Sakr WA (1994) Zonal origin of prostatic adenocarcinoma: are there biologic differences between transition zone and peripheral zone adenocarcinomas of the prostate gland? J Cell Biochem Suppl 19: 267-269. (Pubitemid 24306478)
12. Gutierrez-Canas I, Rodriguez-Henche N, Bolanos O, Carmena M, Prieto J, Juarranz M (2003) VIP and PACAP are autocrine factors that protect the androgenindependent prostate cancer cell line PC-3 from apoptosis induced by serum withdrawal. Br J Pharmacol 139(5): 1050-1058. (Pubitemid 36877404)
13. Houslay M, Baillie G, Maurice D (2007) cAMP-specific phosphodiesterase-4 enzymes in the cardiovascular system - a molecular toolbox for generating compartmentalized cAMP signaling. Circul Res 100(7): 950-966. (Pubitemid 46598920)
14. Houslay MD (2010) Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. Trends Biochem Sci 35(2): 91-100.
15. Houslay MD, Adams DR (2003) PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 370(1): 1-18. (Pubitemid 36259414)
16. Huai Q, Colicelli J, Ke H (2003) The crystal structure of AMP-bound PDE4 suggests a mechanism for phosphodiesterase catalysisw,z. Biochemistry 42(45): 13220-13226. (Pubitemid 37420675)
17. Huang Z, Han Z, Cui W, Zhang F, He H, Zeng T, Sugimoto K, Wu Q (2013) Dynamic expression pattern of Pde4d and its relationship with CpG methylation in the promoter during mouse embryo development. Biochem Biophys Res Commun 441(4): 982-987.
18. Huston E, Houslay T, Baillie G, Houslay M (2006) cAMP phosphodiesterase- 4A1 (PDE4A1) has provided the paradigm for the intracellular targeting of phosphodiesterases, a process that underpins compartmentalized cAMP signalling. Biochem Soc Trans 34: 504-509. (Pubitemid 44230748)
19. Jespersen C, Norgaard M, Bjerklund Johansen T, Sogaard M, Borre M (2011) The influence of cardiovascular morbidity on the prognosis in prostate cancer. Experience from a 12-year nationwide Danish population-based cohort study. BMC Cancer 11(1): 519.
20. Jin S, Bushnik T, Lan L, Conti M (1998) Subcellular localization of rolipramsensitive, cAMP-specific phosphodiesterases - differential targeting and activation of the splicing variants derived from the PDE4D gene. J Biol Chem 273(31): 19672-19678. (Pubitemid 28367024)
21. Kasbohm EA, Guo R, Yowell CW, Bagchi G, Kelly P, Arora P, Casey PJ, Daaka Y (2005) Androgen receptor activation by G(s) signaling in prostate cancer cells. J Biol Chem 280(12): 11583-11589. (Pubitemid 40418471)
22. Keravis T, Lugnier C (2010) Cyclic nucleotide phosphodiesterases (PDE) and peptide motifs. Curr Pharm Design 16(9): 1114-1125.
23. Komiya A, Suzuki H, Imamoto T, Kamiya N, Nihei N, Naya Y, Ichikawa T, Fuse H (2009) Neuroendocrine differentiation in the progression of prostate cancer. Int J Urol 16(1): 37-44.
24. Kvissel A-K, Ramberg H, Eide T, Svindland A, Skålhegg BS, Taskén KA (2007) Androgen dependent regulation of protein kinase A subunits in prostate cancer cells. Cell Signal 19(2): 401-409. (Pubitemid 46017085)
25. Lin B, White JT, Ferguson C, Bumgarner R, Friedman C, Trask B, Ellis W, Lange P, Hood L, Nelson PS (2000) PART-1: A novel human prostate-specific, androgen-regulated gene that maps to chromosome 5q12. Cancer Res 60(4): 858-863. (Pubitemid 30129515)
26. Lin DC, Xu L, Ding LW, Sharma A, Liu LZ, Yang H, Tan P, Vadgama J, Karlan BY, Lester J, Urban N, Schummer M, Doan N, Said JW, Sun HM, Walsh M, Thomas CJ, Patel P, Yin D, Chan D, Koeffler HP (2013) Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers. Proc Natl Acad Sci USA 110(15): 6109-6114.
27. Lynch M, Baillie G, Houslay M (2007) cAMP-specific phosphodiesterase-4D5 (PDE4D5) provides a paradigm for understanding the unique nonredundant roles that PDE4 isoforms play in shaping compartmentalized cAMP cell signalling. Biochem Soc Trans 35: 938-941. (Pubitemid 350206400)
28. Lynch MJ, Baillie GS, Mohamed A, Li X, Maisonneuve C, Klussmann E, van Heeke G, Houslay MD (2005) RNA silencing identifies PDE4D5 as the functionally relevant cAMP phosphodiesterase interacting with beta arrestin to control the protein kinase A/AKAP79-mediated switching of the beta2-adrenergic receptor to activation of ERK in HEK293B2 cells. J Biol Chem 280(39): 33178-33189. (Pubitemid 41397113)
29. MacKenzie KF, Wallace DA, Hill EV, Anthony DF, Henderson DJP, Houslay DM, Arthur JSC, Baillie GS, Houslay MD (2011) Phosphorylation of cAMP-specific PDE4A5 (phosphodiesterase-4A5) by MK2 (MAPKAPK2) attenuates its activation through protein kinase A phosphorylation. Biochem J 435(3): 755-769.
30. MacKenzie S, Baillie G, McPhee I, MacKenzie C, Seamons R, McSorley T, Millen J, Beard M, van Heeke G, Houslay M (2002) Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1). Br J Pharmacol 136(3): 421-433. (Pubitemid 34620523)
31. Marchmont RJ, Houslay MD (1980) A Peripheral and intrinsic enzyme constitute the cyclic-AMP phopsphodiesterase activity of rat-liver plasma-membranes. Biochem J 187(2): 381-392.
32. Marques RB, van Weerden WM, Erkens-Schulze S, de Ridder CM, Bangma CH, Trapman J, Jenster G (2006) The human PC346 xenograft and cell line panel: a model system for prostate cancer progression. Eur Urol 49(2): 245-257. (Pubitemid 43197860)
33. McCahill A, McSorley T, Huston E, Hill EV, Lynch MJ, Gall I, Keryer G, Lygren B, Tasken K, van Heeke G, Houslay MD (2005) In resting COS1 cells a dominant negative approach shows that specific, anchored PDE4 cAMP phosphodiesterase isoforms gate the activation, by basal cyclic AMP production, of AKAP-tethered protein kinase A type II located in the centrosomal region. Cell Signal 17(9): 1158-1173. (Pubitemid 40933535)
34. Merkle D, Hoffmann R (2011) Roles of cAMP and cAMP-dependent protein kinase in the progression of prostate cancer: cross-talk with the androgen receptor. Cell Signal 23(3): 507-515.
35. Murdoch H, Vadrevu S, Prinz A, Dunlop AJ, Klussmann E, Bolger GB, Norman JC, Houslay MD (2011) Interaction between LIS1 and PDE4, and its role in cytoplasmic dynein function. J Cell Sci 124(13): 2253-2266.
36. Ong W, Gribble F, Reimann F, Lynch M, Houslay M, Baillie G, Furman B, Pyne N (2009) The role of the PDE4D cAMP phosphodiesterase in the regulation of glucagon-like peptide-1 release. Br J Pharmacol 157(4): 633-644.
37. Rahrmann EP, Collier LS, Knutson TP, Doyal ME, Kuslak SL, Green LE, Malinowski RL, Roethe L, Akagi K, Waknitz M, Huang W, Largaespada DA, Marker PC (2009) Identification of PDE4D as a Proliferation Promoting Factor in Prostate Cancer Using a Sleeping Beauty Transposon-Based Somatic Mutagenesis Screen. Cancer Res 69(10): 4388-4397.
38. Rampersad S, Ovens J, Huston E, Umana M, Wilson L, Netherton S, Lynch M, Baillie G, Houslay M, Maurice D (2010) Cyclic AMP phosphodiesterase 4D (PDE4D) tethers EPAC1 in a vascular endothelial cadherin (VE-Cad)-based signaling complex and controls cAMP-mediated vascular permeability. J Biol Chem 285(44): 33614-33622.
39. Razzak M (2012) Prostate cancer: cardiovascular risk and androgen deprivation therapy. Nat Rev Urol 9(2): 61-61.
40. Sarwar M, Sandberg S, Abrahamsson P-A, Persson JL (2013) Protein kinase A (PKA) pathway is functionally linked to androgen receptor (AR) in the progression of prostate cancer. Urol Oncol 12(0): 1078-1439.
41. Sidiropoulos M, Chang A, Jung K, Diamandis EP (2001) Expression and regulation of prostate androgen regulated transcript-1 (PART-1) and identification of differential expression in prostatic cancer. Br J Cancer 85(3): 393-397. (Pubitemid 32747708)
42. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CACancer J Clin 63(1): 11-30.
43. Terrin A, Di Benedetto G, Pertegato V, Cheung YF, Baillie G, Lynch MJ, Elvassore N, Prinz A, Herberg FW, Houslay MD, Zaccolo M (2006) PGE(1) stimulation of HEK293 cells generates multiple contiguous domains with different cAMP: role of compartmentalized phosphodiesterases. J Cell Biol 175(3): 441-451. (Pubitemid 44708068)
44. Terrin A, Monterisi S, Stangherlin A, Zoccarato A, Koschinski A, Surdo NC, Mongillo M, Sawa A, Jordanides NE, Mountford JC, Zaccolo M (2012) PKA and PDE4D3 anchoring to AKAP9 provides distinct regulation of cAMP signals at the centrosome. J Cell Biol 198(4): 607-621.
45. Wang D, Deng C, Bugaj-Gaweda B, Kwan M, Gunwaldsen C, Leonard C, Xin X, Hu Y, Unterbeck A, De Vivo M (2003) Cloning and characterization of novel PDE4D isoforms PDE4D6 and PDE4D7. Cell Signal 15(9): 883-891. (Pubitemid 36776662)
46. Wang X, Julio MK-d, Economides KD, Walker D, Yu H, Halili MV, Hu Y-P, Price SM, Abate-Shen C, Shen MM (2009) A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 461(7263): 495-500.
47. Wegiel B, Evans S, Hellsten R, Otterbein LE, Bjartell A, Persson JL (2010) Molecular pathways in the progression of hormone-independent and metastatic prostate cancer. Curr Cancer Drug Targets 10(4): 392-401.
48. Zhang P, He X, Tan J, Zhou X, Zou L (2011) b-Arrestin2 mediates b-2 adrenergic receptor signaling inducing prostate cancer cell progression. Oncol Rep 26(6): 1471-1477.
49. Ückert S, Küthe A, Jonas UDO, Stief CG (2001) Characterisation and functional relevence of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 166(6): 2484-2490. (Pubitemid 33065340)
50. Ückert S, Oelke M, Stief CG, Andersson KE, Jonas U, Hedlund P (2006) Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol 49(4): 740-745. (Pubitemid 43374744)